The PROGRESS Trial: A Prospective Randomized Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement

Brief description of study

This study is being done to see if the SAPIEN 3™ and SAPIEN 3 Ultra™ Transcatheter Heart Valve is beneficial for patients with moderate, calcific aortic stenosis. The SAPIEN 3™ and SAPIEN 3 Ultra™ Transcatheter Heart Valve are not approved by the Food and Drug Administration (FDA) for the treatment of moderate, calcific aortic stenosis and is considered experimental in this research.


Clinical Study Identifier: s21-01143
ClinicalTrials.gov Identifier: NCT04889872


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.